PETReA

What is the study about?

The study is trying to improve treatment for people with follicular lymphoma who need drug treatment for the first time. The study is using a type of body scan called PET-CT to split patients into two groups based on how long their disease is likely to stay away after initial treatment. Those patients whose disease is likely to come back sooner rather than later will be randomly assigned to one of two types of extended treatment, while those whose disease is likely to stay away for a long time will be randomly assigned to receive extended treatment or no further treatment to see how the pros and cons of the two approaches balance out.

Who can take part?

People with follicular lymphoma who need drug treatment for the first time aged over 18 years.

Hospital visits

You see a doctor and have some tests before taking part. The tests might include:

• a physical examination
• blood tests
• heart trace (ECG)
• heart scan (ECHO) 
• CT scan and PET-CT scan
• a bone marrow test

During treatment, you see the trial team regularly. How often you see them depends on the treatment you have. You have a physical examination and blood tests each time you see them.

You have a CT scan before and after induction treatment, and every year after you finish treatment. You also have a PET-CT scan:

• before the start of induction treatment
• 6 weeks after you finish induction treatment
• a year after the start of maintenance treatment if you have a positive PET-CT scan after the induction treatment

When you finish treatment, you see the trial team every 6 months. This continues for as long as you don’t have any signs of the lymphoma coming back.

You stop this study if your lymphoma comes back. Your doctor can tell you which other treatments you might have.

Further details here.

More information

Please visit the study website.

MITHRIDATE

What is the study about?

The aim of this research study is to test how safe and effective a drug called ruxolitinib is when treating patients with PV when compared to the current Best Available Therapy (BAT).

Who can take part?

People with high risk PV

How do I take part?

Please discuss with your doctor at your next clinic appointment.

More information

Visit the study website.

PROPEL

What is the study about?

Treatment for Acute Myeloid Leukaemia (AML) and Myelodysplastic syndrome with excess blasts (MDS-EB2) is extremely challenging and patients often feel very tired (fatigued) have low mood, poor nutrition and be unable to do any exercise. Programmes that help patients improve their overall health and fitness before major treatment is called prehabilitation. This study aims to see if a personalised prehabilitation package which includes remote support for emotional wellbeing, nutrition and exercise can help patients get through all cycles of intensive chemotherapy and stem cell transplant (if given), as well as reduce tiredness, improve quality of life, and treatment outcomes for patients with AML and MDS-EB2.

Who can take part?

People who have been diagnosed with AML or MDS with excess blasts and are, or their blood results suggest they are likely to be in remission after induction chemotherapy. They will also be planning to undertake consolidation chemotherapy with or without a stem cell transplant.

How do I take part?

Please ask at your next clinic appointment.

About

The study will investigate precision medicine approaches to allocate treatment to patients based on the genetics (changes in the genes) of their myeloma and their myeloma’s response to initial treatment. This allows a more personalised approach to treatment rather than the ‘one size fits all’ approach offered as the current standard of care

Can I take part?

Newly diagnosed multiple myeloma patients who are suitable for a stem cell transplant

More information

Please visit Cancer Research UK for more information about this study.